1 |
Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35(5): 473-7.
DOI
ScienceOn
|
2 |
Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 109(4): c182-7.
DOI
ScienceOn
|
3 |
Deryke CA, Crawford AJ, Uddin N, et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54(10): 4503-5.
DOI
ScienceOn
|
4 |
Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009; 37(5): 461-5.
DOI
|
5 |
Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center. Clin Infect Dis 2013; 57(9): 1300-3.
DOI
ScienceOn
|
6 |
Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive care med 2005; 31(8): 1058-65.
DOI
ScienceOn
|
7 |
Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11(2): 115-21.
DOI
ScienceOn
|
8 |
Nam WJ, Shin JH, Han MJ, et al. Clinical significance of acute kidney injury in patients with colistin treatment. Korean J Nephrol 2011; 30: 484-9.
|
9 |
Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138(6): 1333-9.
DOI
ScienceOn
|
10 |
Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011; 62(2): 187-90.
DOI
ScienceOn
|
11 |
Ko H, Jeon M, Choo E, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117(3): c284-8.
DOI
ScienceOn
|
12 |
Kidney function tests. MedlinePlus. http://www.nlm.nih.gov/medlineplus/ency/article/003435.htm (Accessed NOV 05, 2013).
|
13 |
Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40(9): 1333-41.
DOI
ScienceOn
|
14 |
Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Critical care 2003; 7(5): R78-83.
DOI
ScienceOn
|
15 |
Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26(6): 504-7.
DOI
ScienceOn
|
16 |
Kallel H, Bahloul M, Hergafi L, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28(4): 366-9.
DOI
ScienceOn
|
17 |
Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25(1): 11-25.
DOI
ScienceOn
|
18 |
Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10 Suppl 4 :1-9.
|
19 |
Falagas ME, Kasiakou SK, Kofteridis DP, et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-onlysusceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25(9): 596-9.
DOI
|
20 |
Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gramnegative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49(8): 3136-46.
DOI
ScienceOn
|
21 |
Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21(3): 449-65.
DOI
ScienceOn
|
22 |
Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1(1): 14.
DOI
ScienceOn
|
23 |
Kim J, Lee KH, Yoo S, et al. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009; 34(5): 434-8.
DOI
ScienceOn
|
24 |
Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970; 2(20): 923-4.
|
25 |
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Critical care 2006; 10(1): R27.
DOI
|
26 |
Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive care med 2007; 33(7): 1162-7.
DOI
ScienceOn
|
27 |
Micromedex2.0. Colistimethate sodium. http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/B39688/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/E32768/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=2708&contentSetId=31&title=COLISTIMETHATE+SODIUM&servicesTitle=COLISTIMETHATE+SODIUM (Accessed Oct 31, 2013).
|
28 |
Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72(6): 857-68.
DOI
ScienceOn
|
29 |
Goverman J, Weber JM, Keaney TJ, et al. Intravenous colistin for the treatment of multi-drug resistant, gramnegative infection in the pediatric burn population. J Burn Care Res 2007; 28(3): 421-6.
DOI
ScienceOn
|
30 |
Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28(5): 1008-11.
DOI
ScienceOn
|
31 |
Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37(11): e154-60.
DOI
ScienceOn
|
32 |
Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol 1998; 275(2Pt2): F204-15.
|
33 |
Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41(6): 848-54.
DOI
ScienceOn
|
34 |
Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66(9): 2070-4.
DOI
ScienceOn
|
35 |
Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48 (12): 1724-8.
DOI
ScienceOn
|
36 |
Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979; 18(20): 4425-30.
DOI
ScienceOn
|
37 |
Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011; 31(12): 1257-64.
DOI
|